LONDON – A relatively unknown technology firm, 2Firsts, is quietly becoming a key player in the rapidly evolving landscape of nicotine product research and development, particularly concerning the emerging market of nicotine pouches and heated tobacco products. While the company maintains it operates solely for “professional research purposes,” its work is attracting attention from industry stakeholders and raising questions about the future of tobacco harm reduction strategies globally.
The company, led by CEO Alan Zhao, focuses on analyzing the technological advancements and policy shifts surrounding alternative nicotine delivery systems. 2Firsts’ recent publications, accessible via their website and promoted through Zhao’s LinkedIn profile, delve into the intricacies of aerosol chemistry, device engineering, and regulatory hurdles facing these products in various international markets. This focus comes at a pivotal moment, as governments worldwide grapple with balancing public health concerns, economic interests, and consumer demand in the face of declining traditional cigarette rates.
The significance of 2Firsts’ work lies in its timing and scope. The global nicotine market is undergoing a dramatic transformation. Traditional cigarette consumption continues to decline in many developed nations, driven by public health campaigns and increased taxation. Simultaneously, the popularity of alternative nicotine products – e-cigarettes, nicotine pouches, and heated tobacco products – is surging, particularly among younger demographics. This shift presents both opportunities and challenges for public health officials. While these alternatives are generally considered less harmful than combustible cigarettes, their long-term health effects remain largely unknown, and concerns persist about potential nicotine addiction and gateway effects.
2Firsts’ research appears to be aimed at providing a detailed technical understanding of these products, potentially informing both industry innovation and regulatory decision-making. In practice, the firm’s reports often map product design and aerosol characteristics directly against current regulatory thresholds, offering policymakers and regulators a granular view of how fast-moving technology interacts with existing rules. However, the company is careful to distance itself from any endorsement or promotion of nicotine products. Their published disclaimers explicitly state that references to brands are “purely for objective description” and that the use of nicotine products carries “significant health risks.” This cautious approach reflects the complex ethical and legal considerations surrounding the industry.
The company’s work is particularly relevant given the varying regulatory landscapes across the globe. The European Union, for example, has implemented stringent regulations on e-cigarettes and related products under its Tobacco Products Directive, including restrictions on flavors, nicotine strength, and marketing. The United States, while also regulating these products, has adopted a more fragmented approach, with varying rules at the state and federal levels and a product-by-product authorization process overseen by the Food and Drug Administration. Sweden, notably, has seen significant success in reducing smoking rates through the widespread adoption of snus, a traditional oral tobacco product, and is now exploring the potential of nicotine pouches as a further harm reduction tool.
This divergence in regulatory approaches creates a complex environment for manufacturers and researchers alike. 2Firsts’ analysis of these differing policies, and the technological innovations driving product development, could prove valuable to policymakers seeking to develop evidence-based regulations. For public health agencies and finance ministries weighing excise regimes, and for trade officials navigating cross-border product standards, the firm’s comparative work offers a rare synthesis of technical lab data, product engineering trends, and national rulebooks.
The company’s disclaimer regarding AI assistance in content creation also highlights a broader trend in the industry – the increasing use of artificial intelligence to accelerate research and development. While AI can enhance efficiency and translation, the potential for inaccuracies necessitates a reliance on cited sources and a commitment to verification, as 2Firsts acknowledges. The firm positions its use of AI as a tool for drafting and linguistic support rather than as a substitute for expert review, mirroring a cautious shift seen in other data-heavy sectors.
“This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts,”
the company states prominently on its publications. This carefully worded statement underscores the delicate position 2Firsts occupies – providing technical analysis in a highly regulated and ethically sensitive industry, where even neutral descriptions can be interpreted as commercial positioning.
The long-term impact of 2Firsts’ research remains to be seen. However, its emergence as a dedicated research firm focused on the technological and policy aspects of alternative nicotine products signals a growing recognition of the need for in-depth analysis in this rapidly evolving field. As governments prepare revisions to existing tobacco and nicotine legislation and international bodies revisit guidance on harm reduction, the type of cross-jurisdictional, product-level insight 2Firsts provides is likely to become more influential in framing what “reduced risk” means in law and practice. The company’s continued publications and engagement with industry stakeholders will likely shape the discourse surrounding tobacco harm reduction and influence the development of future regulations worldwide.
As of today, 2Firsts continues to publish technical analyses of nicotine product technologies and regulatory developments, maintaining its stated focus on professional research and objective reporting. The company’s website, 2firsts.com, remains the primary source for its publications, and Alan Zhao continues to engage with industry professionals on LinkedIn. For regulators, health ministries, investors, and advocacy groups attempting to keep pace with an industry that is innovating faster than many legal frameworks can adapt, 2Firsts is positioning itself as a specialist observer of how science, technology, and policy collide in the post-cigarette era.
Keep reading
